Cancer Care Overview

An integrative approach to cancer care.

Printable Version

Overview

An Integrative Health approach to cancer care focuses on the whole person, building on what matters most to them and drawing in mindful awareness and self-care along with conventional and complementary approaches to health and well-being. Whether it is exploring cancer prevention, looking at the research related to various therapeutic approaches, or helping a person deal with effects of conventional cancer treatments, Integrative Health can prove beneficial.

Empowerment through Self-Care is key. The Circle of Health highlights eight areas of self-care: Surroundings; Personal Development; Nutrition; Recharge; Family Friends, & Co-Workers; Spirit & Soul; Mind and Emotions; and Physical Activity. Using an example of an Integrative Health visit, this overview and related tools offer an array of options to consider.

Meet The Patient

Pam is a 48-year-old nurse who recently found a painless 1 cm lump in her left breast that grew over the past two months. Her primary care provider ordered a mammogram which showed a concerning lesion. The biopsy revealed estrogen and progesterone negative breast cancer. After a mastectomy and axillary node dissection, it was confirmed that the cancer had metastasized to some of the local lymph nodes. Her oncologist explained that her cancer treatment will need to include chemotherapy and radiation.

Pam is devastated by the news. She has many responsibilities as a single mother of two teenage sons working a full-time job. She is a former smoker with a 25-pack/year history, and the stress of the cancer diagnosis has caused her to pick up smoking again to calm her nerves. In addition, she is having trouble sleeping, which is making her fatigued at work. She is worried that the anxiety will get in the way of providing good nursing care to her patients. Her life stress over the past 10 years has contributed to a 30-pound weight gain, making her overweight.

Pam is also worried about the short- and long-term side effects of treatment. She hates that she will end up losing her long hair and will need a breast implant. Who will take her to and from treatments? Will the chemotherapy leave her too weak to continue working full-time? Who will watch her children during chemo? She is seeking comprehensive care that will include things that will support conventional therapy while reducing side effects. She also wants help making lifestyle changes to reduce the chance of breast cancer recurrence.

Personal Health Inventory

On her Personal Health Inventory (PHI), Pam rates herself a 2 out of 5 for her overall physical well-being and a 1 for overall mental and emotional well-being. When asked what matters most to her and why she wants to be healthy, Pam responds:

“I love spending time with my children. I want to be healthy enough to watch my sons grow up and support them in every way possible. I also want to be a great nurse and touch as many lives as I can.”

For the eight areas of self-care, Pam rates herself on where she is and where she would like to be. She decides to first focus on the areas of Physical Activity and Nutrition by making time for jogging and preparing meals at home.

For more information, check out Pam’s PHI.

Introduction

More than half of cancer patients in the United States use complementary approaches during the survivorship period following acute cancer therapies,1 but up to 60% do not inform their health care team.2 Patients often use complementary therapies because they want to optimize their chances of survival. However, this can challenge and frustrate physicians who have limited knowledge of complementary medicine, thereby discouraging patients to disclose their use.

It is critical to inquire about the use of complementary approaches as a routine part of initial evaluations of cancer patients and to decide together on therapeutic management options at each stage of cancer care. The dangers of not engaging patients in an open discussion of integrative treatments include patients holding false beliefs in a “cure-all” therapy, interactions of supplements and botanicals with chemotherapy and radiation, and patient mistrust of conventional therapies reducing compliance to treatment.

Patients diagnosed with cancer face a different internalization process than those diagnosed with a noncancerous chronic medical condition. It is compounded by periods of extreme fear worsened by the uncertainty of recovery and a heightened awareness of their mortality as the disease progresses. Those with cancer often describe the experience as a journey, which is unique for each individual. Even if the cancer is cured, patients will find themselves adjusting to a “new normal” while they become accustomed to residual side effects from treatment and learning what new symptoms may or may not be concerning for a recurrence.

Important Elements in an Integrative Health Approach to Cancer Care3

  • Communicate empathically with compassion and care.
  • Provide adequate information and knowledge from reliable sources about complementary approaches.
  • Provide psychological, social, and spiritual support.
  • Empower patients and their families.
  • Enable patients to develop strategies for living with cancer and support them in the process.
  • To help cancer patients be truly informed and autonomous, clinicians need to do the following:
    • Learn about conventional treatments that they have tried, failed, or rejected because of safety, quality of life, cost, or other issues.
    • Discover the levels of support that the patient relies on from family, community, faith, and friends.
    • Ask patients about their use of complementary approaches or interest in using complementary medicine.
    • Identify the patient's beliefs, fears, hopes, expectations, and experience with complementary approaches.
    • Acknowledge the patient's spiritual and religious values and beliefs, including views about quality of life and end of life, and seek to understand how these issues affect health care choices.4

Timeline featuring cancer control categories within cancer-related time periods. In pre-diagnosis there is prevention and screening for cancer-related time periods and prevention and detection in cancer control. Post-diagnosis consists of pre-treatment, treatment, survivorship, and end of life. For cancer control, survivorship includes recover/rehabilitation and disease prevention/health promotion. End of life cancer control consists of palliation to survival.

Figure 1. Reprinted with permission from Elsevier, Copyright 20075

Mindful Awareness

Mindful awareness is an overall approach that has relevance for people with many different diagnoses. There are a few studies where its use has been found to benefit people with cancer. A 2013 study of 268 individuals with cancer found that mindful awareness training significantly reduced mood disturbance and stress. Present moment awareness and avoiding judging inner experiences were the two skills most closely linked to improvements in psychological functioning.6 A 2004 study of 59 patients with breast cancer and 10 with prostate cancer found that mindful awareness training (in the form of a mindfulness-based stress reduction course) was associated with enhanced quality of life and decreased symptoms in both groups.7 For more information about the effects of structured mind-body approaches on people with cancer, go to the Mind and Emotions section below, as well as the “Mindful Awareness” overview.

Self-Care

Physical Activity

Exercise

Physical activity and nutrition counseling have not traditionally been part of cancer treatment and survivorship programs. The American Cancer Society (ACS) cites evidence that regular physical activity may reduce the risk for breast, colon, endometrial, and advanced prostate cancer, and possibly pancreatic cancer. The ACS recommends at least 150 minutes of moderate intensity activity or 75 minutes of vigorous-intensity activity a week to see a protective benefit.8 Cancer risk reduction with physical activity ranges from 10%-30%, with best evidence for colon and breast cancer and moderate evidence for endometrial, prostate, and lung cancer.9,10

Four large observational studies have demonstrated that engaging in regular moderate-intensity physical activity after the diagnosis of breast cancer is associated with a 24%-67% reduction in the risk of total deaths and a 50%-53% reduction in the risk of breast cancer deaths compared with women reporting no exercise.11-14 The maximal exercise benefit occurred in those who performed the equivalent of brisk walking 3 hours per week. Two large observational studies have demonstrated that the same amount of physical activity after the diagnosis of colon cancer is associated with a 50%-63% reduction in the risk of total death and a 39%-59% reduction in the risk of colon cancer death relative to people who do not exercise at all.15,16

A prospective cohort study of patients with metastatic lung cancer found that functional capacity, as measured by a 6-minute walk test, was an independent predictor of overall survival. In addition, patients reporting greater than 9 MET-hours of exercise per week had prolonged survival compared with patients who reported less, 26 versus 13 months, respectively.17 (Note: MET-hours is a measure of exercise intensity. It stands for “metabolic equivalents.” This measurement system allows for discussion of the relative intensity of different types of exercise. People burn 1 MET per hour if they are sedentary. Twenty-three METs is the intensity of running close to a 4-minute mile.) A similar prospective cohort study of patients with recurrent malignant glioma found that greater than 9 MET-hours per week of exercise was associated with a median survival of 22 months, whereas less was associated with a median survival of 13 months.18

Cardiorespiratory fitness measured by maximal oxygen uptake (VO2max) is an important predictor of all-cause mortality. Lower VO2max values have been observed in patients with cancer compared to healthy individuals. Longer weekly exercise durations (150 minutes) and larger weekly exercise volumes result in larger beneficial changes of VO2max in patients with cancer who are undergoing treatment.19 For patients receiving treatment for breast cancer, physical performance is better when using a supervised vs. unsupervised training program, and incorporating resistance-training decreases perceived fatigue.20

Exercise also has positive effects on many factors contributing to cancer-related fatigue including muscle strength, cardiopulmonary fitness, aerobic capacity, sleep quality, pain, and mood disturbances, with benefits during or after cancer therapy.21,22 A Cochrane review found that exercise can also have beneficial effects on health-related quality of life, body image and self-esteem, emotional well-being, sexuality, sleep disturbance, social functioning, anxiety, fatigue, and pain.23 Positive effects of exercise interventions are more pronounced with moderate- or vigorous-intensity versus mild-intensity exercise programs.24

Exercise is safe and feasible in patients undergoing neoadjuvant cancer treatment and surgery.25 Improved adherence to exercise programs in cancer patients involves setting program goals, prompting practice and self-monitoring, and encouraging participants to generalize behaviors learned in supervised exercise environments to other, non-supervised contexts. Design exercise prescriptions around individual capabilities. Personalize aerobic exercise, frequency, duration, and intensity. Similarly, tailor resistance training, sets, repetitions, and intensity to each individual.26 For more information check out the “Prescribing Movement” Integrative Health tool.

American Cancer Society Exercise Guidelines

  • Achieve and maintain a healthy weight throughout life.
  • Aim for 150 minutes of moderate-intensity aerobic exercise every week.
  • Start gradually, if not exercising currently.
  • Limit time spent sitting.

Patients who have never exercised before should start with a 10-minute walk and work their way up. Fatigued patients can split their daily exercise into 10-minute blocks. Use caution in patients with bone metastases and recommend a low-intensity supervised exercise program.

Yoga

Yoga reduces distress, anxiety, and depression in breast cancer patients, and it moderately improves fatigue, quality of life, and emotional and social function, both during and post-treatment.27 Cancer patients engaging in yoga have consistent improvement in physical symptoms (heart rate, respiratory rate, immunity, fatigue), psychological symptoms (sleep, depression, distress, and anxiety), and quality of life.28-31

Encourage patients to attend yoga classes for patients with cancer or a chronic illness, as the poses and stretches provide appropriate recognition of physical limitations. Yoga allows participants to work at an individual pace and can be modified for unique circumstances, limiting injuries and harm. Participants should be encouraged to listen to their bodies and not attempt poses uncomfortable or strained poses. The amount of yoga practice necessary to yield positive effects has not yet been determined, and benefits vary from engaging in group sessions to following an instructor on a video watched at home.

Currently, there are no evidence-based guidelines specifying contraindications for yoga for patients with cancer. Patients with symptomatic anemia, postural hypotension, and light-headedness should avoid prolonged standing poses and transition slowly between positions. Patients with balance concerns may modify standing poses by using a chair or wall. Patients with fever, systemic infection, or thrombocytopenia should avoid yoga until their condition improves. During neutropenia, patients should avoid group classes. Recommend that patients purchase their own mats to reduce the risk of exposure to infection. Patients should describe physical limitations or concerns to the yoga instructor and inquire about modifications, availability of props, class size and duration, and suitability for their level of skill and physical ability.32

Qi gong

Qi gong is a general term for a large range of Chinese energy exercises and therapies. “Internal” qi gong is self-directed and involves the use of movements, meditation, and control of breathing pattern. The gentle movements and postures of the exercise are designed to achieve a harmonious flow of qi energy in the body to improve physical fitness and overall well-being. “External” qi gong is performed by a trained practitioner using his or her hands to direct emitted qi energy onto the patient's body for the purpose of diagnosing and treating various diseases. Cancer patients using qi gong exercise in combination with conventional methods have significant reduction in inflammatory markers, 5-year survival rate, fatigue, and cancer-related symptoms. They also have improved blood cell antioxidation capacity.33 Qi gong positively impacts cancer-related quality of life, survival rate, fatigue, distress, sleep, immune function, and leukopenia.34-36

Surroundings

Music therapy

Music therapy is the clinical use of music interventions to address physical, social, emotional, and cognitive needs of a person within a therapeutic relationship facilitated by a credentialed professional. A Cochrane review found that music interventions may benefit anxiety, pain, mood, and quality of life in people with cancer, with further effects on heart rate, respiratory rate, and blood pressure.37 Within a cancer center, a music therapy program can be used to promote patient self-expression, assist patients with music choices to enhance mood and reduce stress, facilitate group interactions with music serving as the catalyst, and promote physical and emotional well-being. Passive music therapy has been shown to reduce anxiety during radiation, chemotherapy, and post-surgery. It is affordable, easy to implement, non-invasive, and does not have any negative effects.30

Environmental exposures: carcinogens and pesticides

Polychlorinated biphenyls. Polychlorinated biphenyls (PCBs) are organochlorides listed as probable human carcinogens by the Environmental Protection Agency. The different forms have various effects, including estrogen modulation, immunotoxicity, and induction of various enzyme systems.38 Increasing evidence supports a strong causal association between exposure to PCBs and non-Hodgkin’s lymphoma (NHL).39,40 However, other reviews have concluded that there is no relationship between PCB exposure and various cancers including prostate, testicular, breast, intestinal, and NHL.41,42 They argue that PCB exposure in rodents leads to a higher burden of the chemical compared to humans due to differences in phase I liver enzyme activation.

Pesticides. Pesticides and herbicides are used on farm crops, lawns, and gardens, and they are also found in household products, including cosmetics. There is a positive relationship between exposure to pesticides and development of some cancers, particularly brain, prostate, kidney, NHL, and leukemia. Studies in pediatric patients indicate an increased risk of cancer associated with prenatal and postnatal exposure, as well as parental exposure at work.43 A longer period of exposure leads to a higher risk.44

Military exposures

Agent Orange. Agent Orange (AO) is a commercial manufactured herbicide that was sprayed extensively during the Vietnam War. During the manufacturing process, it unintendedly was contaminated with the potent carcinogen TCDD, a dioxin. The Institute of Medicine has concluded that there is sufficient evidence to link AO exposure to soft-tissue sarcoma, NHL, Hodgkin’s lymphoma, and chronic lymphocytic leukemia. There is limited evidence to link AO exposure to respiratory cancers, multiple myeloma, and prostate cancer.45 A recent study of 2,720 Veterans who underwent biopsy, revealed that AO exposure was associated with a 52% increase in the overall risk of detecting prostate cancer. Additionally, there was a 75% increase in the risk of high-grade prostate cancer, and a two-fold increase in the risk of prostate cancer with a Gleason score ≥ 8 in Veterans exposed to AO.46 A larger study of 13,144 Veterans reached the same conclusions.47 The risk increases in people with higher TCDD levels or with increasing time spent in Southeast Asia.48 In those who have had a radical prostatectomy, AO exposure is associated with a shorter PSA-doubling time after recurrence.49

Radiation. Uranium ammunition was used during the Persian Gulf War and in the Balkans; this has caused concern about uranium radiation exposure for Veterans who served there. The exposure risk comes from inhalation, ingestion, and the contamination of wounds with shrapnel or dust containing the material. Being enclosed in a tank carrying uranium ammunition would result in less than 25% of the U.S. occupational ionizing radiation exposure limit and would require 250 hours of direct skin contact to exceed the limits for skin. Several reviews have concluded that, although there is a potential for uranium exposure to cause lung cancer, the risk of harm following depleted uranium exposure is low.50-53 The highest mean lifetime risk for lung cancer for a scenario with the longest exposure time of 2 hours was only 0.42%, compared with the background risk of 7.35%.54

Personal Development

Positive thinking

Positive thinking involves the use of mental techniques and strategies to overcome unpleasant, unwanted, and destructive attitudes and states of mind. Cancer patients can use positive mental imagery to influence the body. However, the societal tendency to downplay the negative and emphasize the positive trivializes the legitimacy of a person’s circumstances and the stress they cause. False optimism prevents people from expressing negative feelings, since it results in others being unwilling or unable to hear about them.55 Attempted suppression of negative thoughts and emotions can harm one’s physical health and may decrease immune functioning. Many cancer survivors attribute non-reoccurrence to having a positive attitude, and those who do experience reoccurrence may feel they were not positive enough. It is critical to explain to patients that coping strategies such as positive thinking, having hope, or trying to maintain normalcy may not directly influence their actual control over or responsibility for their cancer outcomes.56

Nutrition

The Standard American Diet (SAD) is low in nutrients and high in inflammatory components including animal fat and chemicals used for processing. In this section, we will discuss the impact of weight, macronutrients (fiber, fats, carbohydrates), and specific foods on cancer.

Weight

Obesity is defined as a body mass index (BMI) greater than 26. The prevalence of obesity is rising, as demonstrated by the Centers for Disease Control and Prevention’s (CDC) Behavioral Risk Factor Surveillance System, and it is contributing to the increased incidence of metabolic syndrome and chronic diseases that accompany it.

The largest prospective analysis on the weight and cancer relationship conducted by the American Cancer Society found that adulthood obesity was associated with increased mortality from colon, breast, endometrial, kidney, esophageal, gastric, pancreatic57, prostate, gallbladder, and liver cancer. This study estimates that 14% of all cancer deaths in men and 20% in women are attributed to being overweight or obese. Those who were severely obese with a BMI greater than 40 had a 52% and 88% risk of all cancer death for men and women, respectively, compared to people of normal body weight.58

Analysis of the Nurses’ Health Study showed that a 5%-10% weight gain within 5 years of a breast cancer diagnosis related to 50% higher rates of breast cancer recurrence and death.59 Women with invasive breast cancer who have a BMI greater than 25 are 2.5 times as likely to die of their disease within 5 years of diagnosis compared with those who have a BMI less than 21.60 For patients with colon cancer, a BMI greater than 35 at diagnosis is associated with a 38% and 49% increased risk of recurrence or death, respectively, compared with a BMI less than 25.61 A BMI greater than 35 is associated with a twofold increase in prostate cancer mortality compared with BMI less than 25.62 Adherence to BMI recommendations can vary from 34%-77% after completion of cancer treatment, so this should be given particular emphasis.63

The mechanisms contributing to tumor promotion include increases in levels of insulin-like growth factor, insulin, leptin, and pro-inflammatory cytokines. The cytokines promote cellular proliferation, inhibit apoptosis, and stimulate growth, migration, and invasion of cancer cells.64,65

Patients should maintain a BMI of 21-26 to reduce the risk of getting cancer or achieve that goal once diagnosed to reduce cancer morbidity and recurrence.

Fiber

The SAD tends to be low in fiber. In general, soluble fiber (e.g., oat bran, flax, psyllium) slows blood glucose absorption and insoluble fiber (e.g., nuts, vegetables, whole wheat) makes bowel movements more regular.

There is a 7% reduction in breast cancer risk for every 10 gm per day increment in dietary fiber intake.66,67 A 2013 prospective study of 11,576 of invasive breast cancer patients confirmed that a diet rich in dietary fiber from vegetables may be associated with a small reduction in risk of breast cancer.68

A high intake of dietary fiber from fruits and vegetables is associated with a reduced risk of colorectal cancer.69 Fiber intake is also associated with a reduced risk of developing pancreatic cancer,70 esophageal cancer,71 head and neck cancer,72 and renal cell cancer.73

Patients should eat 25 gm or more of dietary fiber per day, with fruits and vegetables as the major source.

Fats

There is a weak relationship between total fat intake and prostate and ovarian cancer incidence.74,75 There is no correlation between dietary fat intake and the incidence of breast,76 esophageal, and gastric cancers.77 The Women’s Intervention Nutrition Study found that breast cancer patients who initiated a low-fat diet of less than 31 gm of fat per day had a reduced risk of relapse.78

High consumption of foods containing omega-3 fats such as olive oil, walnuts, avocados, and cold-water fish and low consumption of omega-6 fats reduces the overall incidence of cancer,79 in particular colon, prostate, and breast cancer.80 A recent, oft-criticized study suggests that saturated fat, alpha-linolenic acid (ALA), and eicosapentanoic acid (EPA) intake is related to increased risk of advanced or fatal prostate cancer;81 however, the overall health benefits of omega-3 fats outweigh recommending against their intake. Omega-3 fats may exert their anticancer actions by influencing cell proliferation, cell survival, angiogenesis, inflammation, metastasis, and epigenetic abnormalities.82

Patients should increase intake of omega-3 fats and reduce the intake of saturated and trans fats to reduce the risk of developing cancer.

Red Meat

Red and processed meat (deli meat, hot dogs, sausage) consumption correlates with an increased risk of gastric,83 colon,84-87 esophageal,88 pancreatic,89 breast90, and lung cancer.91 There is no known correlation between red meat consumption and kidney,92 ovarian,93 breast, or prostate cancer.94,95

Patients should limit intake of red meat, particularly processed meat, to no more than 1-2 servings per week.

Soy

Soy foods (miso, tempeh, soybeans, tofu, soy milk) have received attention regarding their influence on cancer, particularly breast cancer. They contain isoflavones, which consist of phytoestrogens and selective estrogen receptor modulators, namely genistein and daidzein. On average, a typical serving of soy (250 gm of soymilk, 100 gm of tofu) contains 20-30 mg of soy isoflavones per serving.

In a 2013 meta-analysis, post-diagnosis soy food consumption was associated with reduced mortality and recurrence in breast cancer patients,96 and when comparing the highest isoflavone intake to the lowest, mortality was reduced 17% and recurrence was reduced 25%.97 Soy consumption reduced recurrence to a greater extent in tamoxifen users, estrogen-receptor negative patients, and postmenopausal women.97 However, prediagnostic soy consumption is not related to decreased mortality from breast cancer in postmenopausal women.98,99

Soy consumption is associated with a reduced risk of gastric and colorectal cancer in women.100,101 Isoflavone-containing foods are associated with a reduced risk of endometrial cancer in postmenopausal women.102,103 Soy food intake may reduce prostate cancer risk.104,105 Prediagnosis soy consumption is associated with better survival in women with lung cancer.106

Patients should eat 1-2 servings of soy foods (preferred over dietary supplements) daily, especially women.

Cruciferous Vegetables

Cruciferous vegetables are in the Brassica family, which includes broccoli, cauliflower, cabbage, bok choy, kohlrabi, kale, arugula, horseradish, mustard greens, turnip greens, collard greens, and watercress, among several others. Their consumption is associated with a reduced incidence of prostate, breast, colon, and bladder cancer.107-109

This protective effect is attributed to isothiocyanates and indoles, namely sulforaphane and indole-3-carbinol, present in these vegetables, which act on the molecular level to decrease oxidative stress, induce apoptosis, suppress cell cycle progression, and inhibit angiogenesis.108,110 These phytochemicals become more bioavailable when cruciferous vegetables are cut, cooked, frozen, pressurized, or thoroughly chewed.

Patients should eat at least 3-4 servings of fruit and 5-6 servings of vegetables daily, 1-2 of which are from cruciferous vegetables.

Mediterranean Diet

A Mediterranean diet (MD) is low in saturated and omega-6 fats (meat, poultry, and dairy), and high in plant sources of monounsaturated fats, omega-3 fats, fiber, antioxidants, and polyphenols (fruit, vegetables, olive oil, and wine). It is associated with a reduction in cancer mortality.111 Adherence to an MD excluding alcohol is related to a modest reduced risk of breast cancer in postmenopausal women,112 but another study done the same year found no effect.113 Eating the MD also correlates with a reduction of colorectal114 and pancreatic cancer risk.115 The MD is not associated with the risk of advanced prostate cancer or disease progression. However, greater adherence to the MD after diagnosis of nonmetastatic prostate cancer was associated with a 220% lower risk of overall mortality.116

Mediterranean diet pyramid: The food that should be consumed in every main meal: fruits, olive oil, bread/pasta/rice, cereals.Third tier (every day): dairy, olives/nuts/seeds, herbs/spices/garlic/onions.Fourth tier (weekly): white meat, potatoes, fish/seafood, eggs, legumes, red should be less than or equal to 2 servings.

Figure 2. Oldways Health Through Heritage Mediterranean Diet. Reprinted with Permission from Oldways.117

American Cancer Society Nutrition Guidelines

  • Eat a healthy diet with an emphasis on plant foods.
  • Limit intake of processed and red meat.
  • Eat at least 2 ½ cups of vegetables and fruit daily.
  • Choose whole grains instead of refined grains.

Recharge

Sleep

Sleep disruption leads to weight gain, metabolic syndrome, and cardiovascular disease. Sleep problems are prevalent in night workers and shift workers. Sleep deprivation impacts heavily upon the entire neuroendocrine-immune system complex that regulates cell proliferation, immune defense (including cytokine production and associated proinflammatory pathways), energy metabolism, and the biological response and adaptation to everyday stresses.118 There is an increased risk of breast cancer in women who work a night shift or rotating shift for at least half a year within 5 or more years preceding their diagnosis.119 A meta-analysis of prospective cohort studies found a 38%-72% decrease in breast cancer for longer sleepers. The same study found a 34% decrease in breast cancer risk in people with the highest urinary melatonin metabolite concentration; people who make more melatonin seem to have lower breast cancer risk.120 However, a more recent meta-analysis concluded that sleep duration has no effect on breast cancer risk.121

Encourage patients to aim for 7-8 hours of sleep daily.

Family, Friends, and Co-Workers

Support groups

Support groups can be very helpful for numerous conditions and are commonly available for cancer survivors. Support groups have a leader who facilitates the group and encourages the sharing of experiences among participants during planned activities. Support groups offer practical help, emotional support, and provide positive feedback. Cancer-related support groups provide a high level of satisfaction. They also improve pain, morale, and quality of life.122,123 One review found that one-on-one, face to-face, and group Internet programs should be given priority as ways to offer peer support.124 The most effective cancer-related support groups provide people with the tools needed to manage the cancer diagnosis, in addition to an emotional outlet. These tools can range from cooking classes to mind-body techniques such as meditation.

Spirit and Soul

Spirituality and prayer are primary strategies for coping with the stress of cancer survival. It is essential for clinicians to screen for spiritual distress, identify spiritual needs, and facilitate appropriate spiritual care at several time points in patients with advanced cancer.125 Religious and spiritual beliefs aid people in accepting their illness and cope with it in a positive and purposeful way. They also influence patients’ decision-making regarding integrative therapies and end-of-life care. Religious beliefs remind people of their identity, give them hope, meaning, and purpose, and allow for connectedness. Unfortunately, the majority of people feel that their spiritual needs are unaddressed during their treatment. The benefits of providing spiritual support include reducing stress and anxiety, improving one’s sense of belonging, strengthening the will to live, and promoting inner peace.

Mind and Emotions

For many people, the diagnosis of cancer is a deeply stressful and emotional experience, which often causes anxiety, depression, and anger. People often fear the diagnosis because of its associated mortality risks, as well as the side effects of treatments. Depending on where a given person with cancer is, in the process of diagnosis and treatment, different concerns will come to the forefront. These concerns can interfere with the patient’s overall well-being and effective participation their own healing process. Mind-body interventions are important for helping patients optimize their course to recovery, in part because they enhance the mind’s capacity to affect bodily functions.

Meditation

Meditation is a mind-body technique that trains the mind in awareness and attention through mental focus on an object, sound, word, phrase, or the breath. Mindfulness meditation involves attending to the whole of an experience nonjudgmentally, without a sense of subject and object. Its primary benefits include relaxation, psychological insight, and decreased stress and pain. Mindfulness-Based Stress Reduction (MBSR) is the most studied form of meditation for cancer patients, and it is a structured 8-week group program of weekly 2.5-hour sessions and one all-day silent retreat. Cancer patients who train in MBSR experience less tension, anger, depression, anxiety, fear, emotional instability, habitual stress behavioral patterns, and fewer concentration problems, and improved immune function.126,127 MBSR significantly reduces anxiety and depression, and promoted sleep quality in patients with cancer, with effects maintained up to 6-12 months after the course.30,128-130 For more information, see the “Mindful Awareness” overview.

Clinical Hypnosis

Hypnosis is a natural state of aroused, attentive focal concentration coupled with relative suspension of peripheral awareness and aims to achieve symptom relief. Relaxation can pair with imagery to reduce the distressing symptom. In cancer patients, clinical hypnosis is effective for reducing pain, anxiety, depression, anticipatory or chemotherapy-related nausea and vomiting, procedural-related pain and distress, and hot flashes.126 Cancer care health care providers should pay attention to what their words may be suggesting to patients, whether or not a formal hypnotic induction is used. Negative suggestions include ‘‘little sting here’’ or ‘‘sharp scratch there’’ while more neutral descriptors are ‘‘some feeling of warmth, coolness, or tingling.’’

Guided Imagery

Guided Imagery involves engaging the imagination to create a sensory experience to achieve a clinical goal. The goal can be specific, such as reducing pain, or general, such as achieving emotional well-being. Often, if coupled with progressive muscle relaxation, it induces the relaxation response. Guided Imagery has been found helpful for anticipatory and chemotherapy-related nausea and vomiting; reducing anxiety, depression, and discomfort; and improving quality of life.127,131 Guided Imagery CDs specific to the various phases of cancer care, including radiation and chemotherapy, have been created by Belleruth Naparstek and can be found at the Health Journeys website.

More information for other types of cancers can be found in the “Colorectal Cancer Care and Prevention” and “Lung Cancer Care and Prevention” tools.

Conventional Approaches

The following is a brief overview of the conventional therapies used in cancer care.132 A full evidence-based review is beyond the scope of this overview.

Surgery

Solid tumors that have not metastasized are removed surgically with clear margins to prevent their spread. Sometimes, surgery can be all that is required. In other cases, surgery is the first part of an overall plan that may include chemotherapy, radiation, or other treatments. Depending on the extent of surgery, the recovery period can range from a couple days to weeks requiring rehabilitation or subsequent surgeries. To ease fears of patients undergoing surgery, help them become comfortable about the procedure, with the surgeon, and where it will take place.

Radiation

Radiation can be used to shrink tumors prior to surgery, eliminate a tumor, help prevent a recurrence, or in palliation to relieve symptoms caused by cancer.133 Often it is recommended with surgery for localized cancers or those in distinct locations in the body. Radiation is a form of ionizing energy delivered through a beam targeted to a tumor or group of cells; the ions trigger cellular apoptosis. Brachytherapy delivers radiation in or near the tumor through pellets placed into the tissue. Side effects of radiation may include anemia, fatigue, gastrointestinal distress, hair loss, skin irritation, and burns. More-serious side effects include fibrosis, secondary cancers, and bone marrow damage.

Chemotherapy

Chemotherapy can be used to help cure cancer, control cancer, and ease symptoms of the disease.134 It is used for cancers not sensitive to radiation or too widely spread. It is the primary treatment for lymphoma, leukemia, and metastasized solid tumors. It is also used to prevent recurrence in early stages of the disease for some types of cancers (e.g., breast) and can be used to shrink tumors prior to surgery. Chemotherapy involves injecting or orally taking chemical agents that are toxic to cells with the goal of halting reproduction and growth. Side effects vary based on the drug and the patient’s sensitivity to it, and may include gastrointestinal distress, hair loss, mouth sores, fatigue, insomnia, anemia, infection, neuropathy, and cardiovascular damage.

Targeted Therapies

These include tyrosine-kinase inhibitors, monoclonal antibodies, and hormonal therapies. Targeted treatment strategies interact with their specific targets to prevent cell division or trigger apoptosis. They are generally better tolerated than chemotherapy, but side effects include rash, gastrointestinal distress, myalgias, and elevated blood pressure.

Complementary Approaches

Massage

Massage Therapy induces relaxation from stress, and the National Comprehensive Cancer Network (NCCN) now recommends massage in its ‘‘Guidelines for Supportive Care,’’ based on the growing body of evidence of massage safety and benefits for quality of life. Swedish massage for cancer patients can alleviate a wide range of symptoms including pain, nausea, anxiety, depression, anger, stress, and fatigue.135 A Cochrane review concluded that massage improves psychological well-being by reducing pain and relieving anxiety.136 The most commonly used protocol of classic massage is twice weekly 30-minute sessions for at least 5 weeks immediately following cancer treatment.30

Massage therapists should have additional knowledge, skill, and experience in safely practicing with cancer patients, which requires specialized training in oncology massage. Typically, pressure should be lighter over bone metastases, areas with peripheral neuropathy, surgical scars, sites of deep vein thrombosis risk, and areas of cancer pain and discomfort. Overall pressure is modified for patients with thrombocytopenia, leukemia, or whenever easy bruising and bleeding are likely. To avoid precipitating a lymphedema episode or triggering chronic lymphedema, oncology massage therapists are careful to avoid heat, pressure, and excessive joint movement in the body region served by the missing or compromised lymph nodes.

Chinese Medicine

Chinese medicine (CM) encompasses the use of herbs, moxibustion, and acupuncture, among many other techniques, to individualize therapy for each person. CM can be very effective at reducing the side effects of cancer treatment including pain, nausea, anxiety/depression, and neuropathy.

For further information on incorporating CM into cancer care, check out the “Managing Side Effects of Chemotherapy and Radiation” Integrative Health tool.

Acupuncture

Acupuncture is an integral part of Chinese medicine and can reduce common side effects experienced by cancer patients undergoing treatment leading to an improved quality of life. Acupuncture can significantly improve pain, chemotherapy-induced nausea and vomiting, cancer-related fatigue, xerostomia (dry mouth), anxiety, depression, and sleep. Nonmedical doctors and physicians can provide acupuncture, but they should have specific training in oncology. Precautions should be taken to prevent bacterial contamination, avoid limbs with lymphedema, and apply needles to easily compressible sites in patients with a bleeding tendency. Six to eight sessions are needed to determine whether acupuncture is effective for the patient.137,138

For further discussion on acupuncture’s role in the management of cancer treatment side effects, go to the “Managing Chemotherapy-Induced Nausea and Vomiting,” and “Managing Side Effects of Chemotherapy and Radiation” Integrative Health tools.

Dietary Supplements

Note: Dietary supplements are intended to supplement the diet. They are not medicines and are not intended to treat, diagnose, mitigate, prevent, or cure disease. In some cases, dietary supplements may have unwanted effects, especially if taken before surgery or with other dietary supplements or medicines, or if you have certain health conditions. Also, supplements are not regulated with the same degree of oversight as medications. Products vary greatly in terms of accuracy of labels, presence of contaminants, and the validity of claims on the label. Work with your health care provider to determine how best to achieve optimal health.

Vitamin D

High vitamin D levels are associated with a lower risk of breast,139-142, colorectal,143-145 thyroid,146,147 bladder,148-150 and lung151,152 cancers. Higher levels of circulating vitamin D reduce breast cancer mortality in a dose-dependent manner.146 Several studies indicate that vitamin D levels do not correlate with prostate,153-156 esophageal,157 or gastric cancers risk.158 A study of Veterans with bladder cancer found that a higher vitamin D level was linked to longer survival.159 A large systematic review and meta-analysis found that vitamin D supplementation does not reduce the incidence of cancer or cancer mortality.160 Some foods (eggs, fortified dairy, mushrooms, and fish) provide small amounts of vitamin D2 (ergocalciferol), but ultraviolet light from the sun is the best source of vitamin D3 (cholecalciferol). Vitamin D production is impaired with age, obesity, and pigmentation, so oral supplementation is advised.

  • Dose: Each 1000 IU of vitamin D3 should increase 25-hydroxyvitamin D levels by 10 ng/ml. A safe recommendation is to achieve a 25-hydroxyvitamin D level in the 50-80 ng/ml range.
Antioxidants

The use of antioxidants (vitamins A, C, E, selenium, and carotenoids) during cancer treatment is controversial due to the theoretical risk of reducing the number of free radicals created by chemoradiotherapy. Since free radicals target and kill cancer cells, suppressing production can reduce the effectiveness of cancer treatment. Antioxidants have not been found to prevent gastric,161 skin,162 prostate,163 or colon cancers.164 Other meta-analyses found that antioxidants do not prevent any cancer.165-167 Beta-carotene increases lung cancer risk in people who smoke and have asbestosis.168 Preliminary evidence suggests that high-dose intravenous antioxidants during chemotherapy can reduce side effects and potentiate treatment effects, but that is beyond the scope of this discussion as specific therapeutic recommendations cannot yet been made.

Do not recommend that your patients start on antioxidants to prevent cancer, but rather encourage a high intake of fruits (especially berries and dark grapes) and brightly colored vegetables to obtain them naturally.

For more information, see the “Supplement/Botanical Interactions with Chemotherapy and Radiation” Integrative Health tool.

Curcumin

Curcumin is the major component of the Indian spice turmeric (Curcuma longa) and has anti-inflammatory and chemo-preventative properties. Curcumin inhibits COX-2 activity and TNF-alpha signaling pathways and regulates the expression of p53 tumor suppressing gene.169 Curcumin has reported activity against leukemia and lymphoma, gastrointestinal cancers, pancreatic cancer, genitourinary cancers, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, lung cancer, melanoma, neurological cancers, and sarcoma.170 It has also been shown to protect normal organs such as liver, kidney, oral mucosa, and heart from chemoradiotherapy-induced toxicity.171

  • Dose: 500-3,000 mg daily combined with piperine (black pepper) to increase bioavailability and taken during meals containing healthy fats to enhance absorption.
Green Tea

Green tea consists of unfermented Camellia sinensis tea leaves with a high polyphenol content, 40% of which is epigallocatechin gallate (EGCG). Green tea consumption is associated with a reduced incidence and recurrence of breast cancer.172-175 Green tea may have protective effects against developing primary prostate cancer176-179 and non-Hodgkin’s lymphoma,180 with mixed evidence for gynecologic,181-186 esophageal,187,188 gastric,189,190 and liver cancers,191-194 and no evidence for colorectal cancer.195,196

  • Dose: Recommended green tea intake is 3 to 5 cups per day (up to 1,200 ml daily), providing a minimum of 250 mg daily catechins. Liver enzymes should be monitored in patients taking high-dose green tea supplements.
  • Interactions: May inhibit the enzyme CYP450 3A4 (needed to help remove foreign substances from the body) if using more than 800 mg daily, and may increase tamoxifen bioavailability.170
Melatonin

Melatonin is a hormone secreted by the pineal gland that regulates sleep patterns. Its actions include stimulating growth hormone production, triggering apoptosis, up-regulation of antioxidant enzymes, suppression of tumor and endothelial growth factors, and down-regulation of pro-oxidative enzymes.170 There is an improved effect of chemoradiotherapy and 1-year survival rates among cancer patients with complete response, partial response, and stable disease using melatonin as adjuvant treatment. Melatonin significantly reduce fatigue, neurotoxicity, asthenia, leukopenia, nausea and vomiting, hypotension, and thrombocytopenia from chemotherapy.197,198

  • Dose: The adjuvant dose is 20 mg at night, and it can cause sedation, vivid dreams, and headaches. For insomnia, the dose is 1-10 mg at night. The effective dose varies greatly from one person to another, in terms of sleep effects.

For more information, go to the “Mycomedicinals (Mushrooms) for Cancer” and “Supplement/Botanical Interactions with Chemotherapy and Radiation” Integrative Health tools.

Personal Health Plan

Name: Pam

Date: xx/xx/xxxx

Meaning, Aspiration, Purpose (MAP):

My mission is to get through breast cancer treatment with minimal side effects while improving my health, and to become more in touch with my spirituality and find inner peace.

My Goals:
  • Start running 3 times a week.
  • Learn how to cook meals at home to improve nutrition and lose 30 lbs.
  • Clear the clutter by having a more-structured daily schedule, allowing enough time for sleep, family, and myself.
My Plan for Skill Building and Support
Mindful Awareness:
  • Pay more attention to when I am pushing my limits too much, whether it is at work or at home. Engage my sons in helping take some of the load off my responsibilities at home.
  • Run, to clear the clutter in my head and move from stressful thought patterns to healthier, more emotionally sound ones.
  • Keep a gratitude journal every night and write one thing in it that I am grateful for.
Areas of Self-Care:
  • Physical Activity
    • Start running regularly and aim for 3 hours per week. Try getting my sons into it as well, to train for a half marathon together in the upcoming months. To work on the mind-body aspect of exercise, try a free tai chi class at the cancer resource center.
  • Surroundings
    • Work with my sons to keep the house tidy and free of clutter. Speak with my Primary Care Physician about ways to quit smoking when I am ready.
  • Personal Development
    • Join a knitting group to socialize with new people. To achieve work-life balance, start thinking about giving up one of my board positions at the hospital.
  • Nutrition
    • Follow an anti-inflammatory diet by minimizing refined sugars and processed foods in my diet. Take a healthy cooking class with my sons so that we can cook together.
  • Recharge
    • Aim for 8 hours of sleep a night. Try to minimize night shifts at work. Stop drinking caffeine after 12 pm.
  • Family, Friends, and Co-Workers
    • Do more activities with my sons. In addition, use this time to get closer with my mother.
  • Spirit and Soul
    • Explore finding a spiritual anchor through mindfulness meditation. Join an 8-week Mindfulness-Based Stress Reduction course to help through this journey. Alternatively, I can start by listening to the audiobook “Mindfulness for Beginners” by Jon Kabat-Zinn and reading his book “Full Catastrophe Living.”
  • Mind and Emotions
    • Start with deep breathing exercises at night to help relax before going to bed. Maybe seek the help of a therapist to address anxiety and worries.
Professional Care: Conventional and Complementary
  • Prevention/Screening
    • Up-to-date on PAPs, screening labs, and immunization
  • Treatment (e.g., conventional and complementary approaches, medications, and supplements)
    • Start treatment plan per the oncologist.
    • Consider massage therapy to help with anxiety.
    • Continue current medications.
    • Take melatonin 5-20 mg at night to help sleep as this also has anti-cancer properties
  • Skill building and education
    • Mindfulness-based stress reduction, breathwork, and Guided Imagery resources
    • Anti-inflammatory diet
Referrals/Consults
  • Oncology rehab therapy to prevent lymphedema and cording postoperatively, or to treat neuropathy from chemotherapy
  • Psychologist for counseling
  • Massage therapist
Community
  • Support groups through the local health system or American Cancer Society
Resources
  • Meditation phone apps: Calm, Headspace
  • Books: Mindfulness for Beginners, by Jon Kabat-Zinn
My Support Team
  • Principal Professions
    • Primary Care Clinician
    • Oncologist
    • Psychotherapist
  • Personal
    • Best friend, Anne
    • Sons, Mike and Nick
    • Co-worker, Linda
Next Steps
  • Sign up for cooking class.
  • Keep a food and exercise log to meet my goals.
  • Follow up with an oncologist as scheduled.
  • Follow up with the team in 1-2 months.

Please Note: This plan is for my personal use and does not comprise my complete medical or pharmacological data, nor does it replace my medical record.

Follow-Up With Pam

In the past two months, Pam has started running 5 times a week in the morning before she goes to work. After much deliberation, she decided to give up one of her board positions at the hospital so she could have more time for herself and her family. She and her sons love spending time cooking dinner together. She has made some new friends at her weekly knitting sessions and uses it as therapy to help reduce her anxiety. The melatonin has helped her sleep better, and she has stopped smoking with the use of smoking cessation medication.

She is receiving chemotherapy treatments currently and experiencing a significant amount of nausea. But she uses ginger and peppermint tea to help control her symptoms, along with the prescribed anti-nausea medications. She is also taking supplements to enhance the effectiveness of the chemotherapy and reduce side effects like neuropathy and fatigue. Overall, she has a much more positive attitude, and the breast cancer diagnosis has given her a new outlook on life.

Next month, she hopes to join a local mindfulness course to learn mindfulness meditation. Now that she has more time in her life, she also will be reconnecting more with her mother. She is thankful that she has been able to work with you to reach her health goals during a very stressful time in her life.

Integrative Health Tools

Resources

Organizations

Exercise Tools

What we know about integrative health care has come to us thanks to the efforts, experiences, and collective wisdom of people from many cultures and backgrounds. We wish to acknowledge all the healers, researchers, patients, and peoples who have informed the content of this tool.

Author(s)

This handout was adapted for the Osher Center for Integrative Health at the University of Wisconsin-Madison from the original by Srivani Sridhar, MD.

Date Created: 2014, Updated: 2020

Modified for UW Integrative Health: 2021

References

  1. Gansler T, Kaw C, Crammer C, Smith T. A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society's studies of cancer survivors. Cancer. Sep 1 2008;113(5):1048-57. doi:10.1002/cncr.23659
  2. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. Jul 2000;18(13):2505-14.
  3. Frenkel M. Clinical consultation, a personal perspective: components of a successful integrative medicine clinical consultation. Journal of the Society for Integrative Oncology. Summer 2008;6(3):129-33.
  4. Frenkel M, Ben-Arye E, Baldwin CD, Sierpina V. Approach to communicating with patients about the use of nutritional supplements in cancer care. South Med J. Mar 2005;98(3):289-94.
  5. Courneya KS, Friedenreich CM. Physical activity and cancer control. Semin Oncol Nurs. 2007;23(4):242-252.
  6. Garland SN, Tamagawa R, Todd SC, Speca M, Carlson LE. Increased mindfulness is related to improved stress and mood following participation in a mindfulness-based stress reduction program in individuals with cancer. Integr Cancer Ther. 2013;12(1):31-40.
  7. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology. 2004;29(4):448-474.
  8. Kushi LH, Doyle C, McCullough M, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. Jan-Feb 2012;62(1):30-67. doi:10.3322/caac.20140
  9. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. Eur J Cancer. Sep 2010;46(14):2593-604. doi:10.1016/j.ejca.2010.07.028
  10. Wiggins MS, Simonavice EM. Cancer prevention, aerobic capacity, and physical functioning in survivors related to physical activity: a recent review. Cancer Manag Res. 2010;2:157-64.
  11. Irwin ML, Smith AW, McTiernan A, et al. Influence of pre-and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol. 2008;26(24):3958-3964.
  12. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. May 25 2005;293(20):2479-86. doi:10.1001/jama.293.20.2479
  13. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. Feb 2008;17(2):379-86. doi:10.1158/1055-9965.epi-07-0771
  14. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. Jun 10 2007;25(17):2345-51. doi:10.1200/jco.2006.08.6819
  15. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. Aug 1 2006;24(22):3527-34. doi:10.1200/jco.2006.06.0855
  16. Meyerhardt JA, Heseltine D, Niedzwiecki D, et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. Aug 1 2006;24(22):3535-41. doi:10.1200/jco.2006.06.0863
  17. Jones LW, Hornsby WE, Goetzinger A, et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer. May 2012;76(2):248-52. doi:10.1016/j.lungcan.2011.10.009
  18. Ruden E, Reardon DA, Coan AD, et al. Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. Jul 20 2011;29(21):2918-23. doi:10.1200/jco.2011.34.9852
  19. Bjørke ACH, Sweegers MG, Buffart LM, Raastad T, Nygren P, Berntsen S. Which exercise prescriptions optimize V̇O(2) max during cancer treatment? A systematic review and meta-analysis. Scand J Med Sci Sports. Sep 2019;29(9):1274-1287. doi:10.1111/sms.13442
  20. Gebruers N, Camberlin M, Theunissen F, et al. The effect of training interventions on physical performance, quality of life, and fatigue in patients receiving breast cancer treatment: a systematic review. Support Care Cancer. Jan 2019;27(1):109-122. doi:10.1007/s00520-018-4490-9
  21. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11:Cd006145. doi:10.1002/14651858.CD006145.pub3
  22. Loughney LA, West MA, Kemp GJ, Grocott MP, Jack S. Exercise interventions for people undergoing multimodal cancer treatment that includes surgery. Cochrane Database Syst Rev. Dec 11 2018;12(12):Cd012280. doi:10.1002/14651858.CD012280.pub2
  23. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev. 2012;8:Cd007566. doi:10.1002/14651858.CD007566.pub2
  24. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. Clin Otolaryngol. Oct 2012;37(5):390-2. doi:10.1111/coa.12015
  25. Loughney L, West MA, Kemp GJ, Grocott MP, Jack S. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: A systematic review. Eur J Surg Oncol. Jan 2016;42(1):28-38. doi:10.1016/j.ejso.2015.09.027
  26. Bourke L, Homer KE, Thaha MA, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Database Syst Rev. 2013;9:Cd010192. doi:10.1002/14651858.CD010192.pub2
  27. Buffart LM, Van Uffelen JG, Riphagen II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2012;12(1):559. doi:10.1186/1471-2407-12-559
  28. Danhauer SC, Addington EL, Sohl SJ, Chaoul A, Cohen L. Review of yoga therapy during cancer treatment. Support Care Cancer. Apr 2017;25(4):1357-1372. doi:10.1007/s00520-016-3556-9
  29. Agarwal RP, Maroko-Afek A. Yoga into cancer care: a review of the evidence-based research. Int J Yoga. Jan-Apr 2018;11(1):3-29. doi:10.4103/ijoy.IJOY_42_17
  30. Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. May 6 2017;67(3):194-232. doi:10.3322/caac.21397
  31. Lin PJ, Peppone LJ, Janelsins MC, et al. Yoga for the management of cancer treatment-related toxicities. Curr Oncol Rep. Feb 1 2018;20(1):5. doi:10.1007/s11912-018-0657-2
  32. DiStasio SA. Integrating yoga into cancer care. Clin J Oncol Nurs. Feb 2008;12(1):125-30. doi:10.1188/08.cjon.125-130
  33. Chan CL, Wang CW, Ho RT, et al. A systematic review of the effectiveness of qigong exercise in supportive cancer care. Support Care Cancer. Jun 2012;20(6):1121-33. doi:10.1007/s00520-011-1378-3
  34. Oh B, Butow P, Mullan B, et al. A critical review of the effects of medical Qigong on quality of life, immune function, and survival in cancer patients. Integr Cancer Ther. Jun 2012;11(2):101-10. doi:10.1177/1534735411413268
  35. Klein PJ, Schneider R, Rhoads CJ. Qigong in cancer care: a systematic review and construct analysis of effective Qigong therapy. Support Care Cancer. Jul 2016;24(7):3209-22. doi:10.1007/s00520-016-3201-7
  36. Zeng Y, Xie X, Cheng ASK. Qigong or tai chi in cancer care: an updated systematic review and meta-analysis. Curr Oncol Rep. Apr 6 2019;21(6):48. doi:10.1007/s11912-019-0786-2
  37. Bradt J, Dileo C, Grocke D, Magill L. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev. 2011;(8):Cd006911. doi:10.1002/14651858.CD006911.pub2
  38. Kramer S, Hikel SM, Adams K, Hinds D, Moon K. Current status of the epidemiologic evidence linking polychlorinated biphenyls and non-hodgkin lymphoma, and the role of immune dysregulation. Environ Health Perspect. Aug 2012;120(8):1067-75. doi:10.1289/ehp.1104652
  39. Engel LS, Lan Q, Rothman N. Polychlorinated biphenyls and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. Mar 2007;16(3):373-6. doi:10.1158/1055-9965.epi-07-0055
  40. Freeman MD, Kohles SS. Plasma levels of polychlorinated biphenyls, non-Hodgkin lymphoma, and causation. Journal of environmental and public health. 2012;2012:258981. doi:10.1155/2012/258981
  41. Golden R, Kimbrough R. Weight of evidence evaluation of potential human cancer risks from exposure to polychlorinated biphenyls: an update based on studies published since 2003. Crit Rev Toxicol. 2009;39(4):299-331. doi:10.1080/10408440802291521
  42. Zani C, Toninelli G, Filisetti B, Donato F. Polychlorinated biphenyls and cancer: an epidemiological assessment. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31(2):99-144. doi:10.1080/10590501.2013.782174
  43. Bassil KL, Vakil C, Sanborn M, Cole DC, Kaur JS, Kerr KJ. Cancer health effects of pesticides: systematic review. Can Fam Physician. Oct 2007;53(10):1704-11.
  44. Merhi M, Raynal H, Cahuzac E, Vinson F, Cravedi JP, Gamet-Payrastre L. Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case-control studies. Cancer Causes Control. Dec 2007;18(10):1209-26. doi:10.1007/s10552-007-9061-1
  45. Institute of Medicine, Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides. Veterans and Agent Orange: Update 2012. The National Academies Press; 2014.
  46. Ansbaugh N, Shannon J, Mori M, Farris PE, Garzotto M. Agent Orange as a risk factor for high-grade prostate cancer. Cancer. Jul 1 2013;119(13):2399-404. doi:10.1002/cncr.27941
  47. Chamie K, DeVere White RW, Lee D, Ok JH, Ellison LM. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. Nov 1 2008;113(9):2464-70. doi:10.1002/cncr.23695
  48. Pavuk M, Michalek JE, Ketchum NS. Prostate cancer in US Air Force veterans of the Vietnam war. J Expo Sci Environ Epidemiol. Mar 2006;16(2):184-90. doi:10.1038/sj.jea.7500448
  49. Shah SR, Freedland SJ, Aronson WJ, et al. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. May 2009;103(9):1168-72. doi:10.1111/j.1464-410X.2009.08405.x
  50. Bolton JP, Foster CR. Battlefield use of depleted uranium and the health of veterans. J R Army Med Corps. Sep 2002;148(3):221-9.
  51. Bem H, Bou-Rabee F. Environmental and health consequences of depleted uranium use in the 1991 Gulf War. Environ Int. Mar 2004;30(1):123-34. doi:10.1016/s0160-4120(03)00151-x
  52. Sztajnkrycer MD, Otten EJ. Chemical and radiological toxicity of depleted uranium. Mil Med. Mar 2004;169(3):212-6.
  53. Marshall AC. Gulf war depleted uranium risks. J Expo Sci Environ Epidemiol. Jan 2008;18(1):95-108. doi:10.1038/sj.jes.7500551
  54. Hahn FF, Roszell LE, Daxon EG, Guilmette RA, Parkhurst MA. Radiological risk assessment of Capstone depleted uranium aerosols. Health Phys. Mar 2009;96(3):352-62. doi:10.1097/01.hp.0000318891.68749.66
  55. De Raeve L. Positive thinking and moral oppression in cancer care. Eur J Cancer Care (Engl). Dec 1997;6(4):249-56.
  56. Ruthig JC, Holfeld B, Hanson BL. The role of positive thinking in social perceptions of cancer outcomes. Psychol Health. 2012;27(10):1244-58. doi:10.1080/08870446.2012.666549
  57. Carreras-Torres R, Johansson M, Gaborieau V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a mendelian randomization study. J Natl Cancer Inst. Sep 1 2017;109(9)doi:10.1093/jnci/djx012
  58. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. Apr 24 2003;348(17):1625-38. doi:10.1056/NEJMoa021423
  59. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. Mar 1 2005;23(7):1370-8. doi:10.1200/jco.2005.01.079
  60. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. Aug 15 2001;92(4):720-9.
  61. Dignam JJ, Polite BN, Yothers G, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. Journal of the National Cancer Institute. Nov 15 2006;98(22):1647-54. doi:10.1093/jnci/djj442
  62. Wright ME, Chang SC, Schatzkin A, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. Feb 15 2007;109(4):675-84. doi:10.1002/cncr.22443
  63. Tjon AJS, Pannekoek S, Kampman E, Hoedjes M. Adherence to diet and body weight recommendations among cancer survivors after completion of initial cancer treatment: A systematic review of the literature. Nutr Cancer. 2019;71(3):367-374. doi:10.1080/01635581.2018.1540713
  64. King B, Jiang Y, Su X, et al. Weight control, endocrine hormones and cancer prevention. Experimental biology and medicine (Maywood, NJ). May 2013;238(5):502-8. doi:10.1177/1535370213480695
  65. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci. Oct 2012;1271:37-43. doi:10.1111/j.1749-6632.2012.06750.x
  66. Aune D, Chan DS, Greenwood DC, et al. Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies. Ann Oncol. Jun 2012;23(6):1394-402. doi:10.1093/annonc/mdr589
  67. Li Q, Holford TR, Zhang Y, et al. Dietary fiber intake and risk of breast cancer by menopausal and estrogen receptor status. Eur J Nutr. Feb 2013;52(1):217-23. doi:10.1007/s00394-012-0305-9
  68. Ferrari P, Rinaldi S, Jenab M, et al. Dietary fiber intake and risk of hormonal receptor-defined breast cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr. Feb 2013;97(2):344-53. doi:10.3945/ajcn.112.034025
  69. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2011;343:d6617. doi:10.1136/bmj.d6617
  70. Bidoli E, Pelucchi C, Zucchetto A, et al. Fiber intake and pancreatic cancer risk: a case-control study. Ann Oncol. Jan 2012;23(1):264-8. doi:10.1093/annonc/mdr060
  71. Coleman HG, Murray LJ, Hicks B, et al. Dietary fiber and the risk of precancerous lesions and cancer of the esophagus: a systematic review and meta-analysis. Nutr Rev. Jul 2013;71(7):474-82. doi:10.1111/nure.12032
  72. Lam TK, Cross AJ, Freedman N, et al. Dietary fiber and grain consumption in relation to head and neck cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control. Oct 2011;22(10):1405-14. doi:10.1007/s10552-011-9813-9
  73. Daniel CR, Park Y, Chow WH, Graubard BI, Hollenbeck AR, Sinha R. Intake of fiber and fiber-rich plant foods is associated with a lower risk of renal cell carcinoma in a large US cohort. Am J Clin Nutr. May 2013;97(5):1036-43. doi:10.3945/ajcn.112.045351
  74. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. Journal of the National Cancer Institute. 1993;85(19):1571-1579.
  75. Blank MM, Wentzensen N, Murphy MA, Hollenbeck A, Park Y. Dietary fat intake and risk of ovarian cancer in the NIH-AARP Diet and Health Study. Br J Cancer. Jan 31 2012;106(3):596-602. doi:10.1038/bjc.2011.572
  76. Park SY, Kolonel LN, Henderson BE, Wilkens LR. Dietary fat and breast cancer in postmenopausal women according to ethnicity and hormone receptor status: the Multiethnic Cohort Study. Cancer prevention research (Philadelphia, Pa). Feb 2012;5(2):216-28. doi:10.1158/1940-6207.capr-11-0260
  77. O'Doherty MG, Freedman ND, Hollenbeck AR, et al. Association of dietary fat intakes with risk of esophageal and gastric cancer in the NIH-AARP diet and health study. Int J Cancer. Sep 15 2012;131(6):1376-87. doi:10.1002/ijc.27366
  78. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. Journal of the National Cancer Institute. Dec 20 2006;98(24):1767-76. doi:10.1093/jnci/djj494
  79. de Lorgeril M, Salen P. New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids. BMC Med. 2012;10:50. doi:10.1186/1741-7015-10-50
  80. Gerber M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br J Nutr. Jun 2012;107 Suppl 2:S228-39. doi:10.1017/s0007114512001614
  81. Pelser C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev. Apr 2013;22(4):697-707. doi:10.1158/1055-9965.epi-12-1196-t
  82. Jing K, Wu T, Lim K. Omega-3 polyunsaturated fatty acids and cancer. Anticancer Agents Med Chem. Oct 2013;13(8):1162-77.
  83. Zhu H, Yang X, Zhang C, et al. Red and processed meat intake is associated with higher gastric cancer risk: a meta-analysis of epidemiological observational studies. PLoS One. 2013;8(8):e70955. doi:10.1371/journal.pone.0070955
  84. Hsing AW, McLaughlin JK, Chow WH, et al. Risk factors for colorectal cancer in a prospective study among U.S. white men. Int J Cancer. Aug 12 1998;77(4):549-53.
  85. Xu X, Yu E, Gao X, et al. Red and processed meat intake and risk of colorectal adenomas: a meta-analysis of observational studies. International Journal of Cancer. Jan 15 2013;132(2):437-448. doi:10.1002/ijc.27625
  86. Aune D, Chan DS, Vieira AR, et al. Red and processed meat intake and risk of colorectal adenomas: a systematic review and meta-analysis of epidemiological studies. Cancer causes & control : CCC. Apr 2013;24(4):611-627. doi:10.1007/s10552-012-0139-z
  87. Steck SE, Guinter M, Zheng J, Thomson CA. Index-based dietary patterns and colorectal cancer risk: a systematic review. Adv Nutr. Nov 2015;6(6):763-73. doi:10.3945/an.115.009746
  88. Huang W, Han Y, Xu J, Zhu W, Li Z. Red and processed meat intake and risk of esophageal adenocarcinoma: a meta-analysis of observational studies. Cancer Causes Control. Jan 2013;24(1):193-201. doi:10.1007/s10552-012-0105-9
  89. Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer. Jan 31 2012;106(3):603-7. doi:10.1038/bjc.2011.585
  90. Bella F, Godos J, Ippolito A, Di Prima A, Sciacca S. Differences in the association between empirically derived dietary patterns and cancer: a meta-analysis. Int J Food Sci Nutr. Jun 2017;68(4):402-410. doi:10.1080/09637486.2016.1261087
  91. Gnagnarella P, Maisonneuve P, Bellomi M, et al. Red meat, Mediterranean diet and lung cancer risk among heavy smokers in the COSMOS screening study. Ann Oncol. Oct 2013;24(10):2606-11. doi:10.1093/annonc/mdt302
  92. Alexander DD, Cushing CA. Quantitative assessment of red meat or processed meat consumption and kidney cancer. Cancer Detect Prev. 2009;32(5-6):340-51. doi:10.1016/j.cdp.2009.02.002
  93. Wallin A, Orsini N, Wolk A. Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies. Br J Cancer. Mar 29 2011;104(7):1196-201. doi:10.1038/bjc.2011.49
  94. Alexander DD, Morimoto LM, Mink PJ, Cushing CA. A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev. Dec 2010;23(2):349-65. doi:10.1017/s0954422410000235
  95. Alexander DD, Mink PJ, Cushing CA, Sceurman B. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. Nutr J. 2010;9:50. doi:10.1186/1475-2891-9-50
  96. Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 2013;14(4):2407-12.
  97. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. Jul 2012;96(1):123-32. doi:10.3945/ajcn.112.035972
  98. Conroy SM, Maskarinec G, Park SY, Wilkens LR, Henderson BE, Kolonel LN. The effects of soy consumption before diagnosis on breast cancer survival: the Multiethnic Cohort Study. Nutr Cancer. 2013;65(4):527-37. doi:10.1080/01635581.2013.776694
  99. Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. Jan 2011;125(2):315-23. doi:10.1007/s10549-010-1270-8
  100. Ko KP, Park SK, Yang JJ, et al. Intake of soy products and other foods and gastric cancer risk: a prospective study. J Epidemiol. Sep 5 2013;23(5):337-43.
  101. Yan L, Spitznagel EL, Bosland MC. Soy consumption and colorectal cancer risk in humans: a meta-analysis. Cancer Epidemiol Biomarkers Prev. Jan 2010;19(1):148-58. doi:10.1158/1055-9965.epi-09-0856
  102. Ollberding NJ, Lim U, Wilkens LR, et al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. J Natl Cancer Inst. Jan 4 2012;104(1):67-76. doi:10.1093/jnci/djr475
  103. Myung SK, Ju W, Choi HJ, Kim SC. Soy intake and risk of endocrine-related gynaecological cancer: a meta-analysis. BJOG. Dec 2009;116(13):1697-1705. doi:10.1111/j.1471-0528.2009.02322.x
  104. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer. 2009;61(5):598-606. doi:10.1080/01635580902825639
  105. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr. Apr 2009;89(4):1155-63. doi:10.3945/ajcn.2008.27029
  106. Yang G, Shu XO, Li HL, et al. Prediagnosis soy food consumption and lung cancer survival in women. J Clin Oncol. Apr 20 2013;31(12):1548-53. doi:10.1200/jco.2012.43.0942
  107. Liu B, Mao Q, Cao M, Xie L. Cruciferous vegetables intake and risk of prostate cancer: a meta-analysis. Int J Urol. Feb 2012;19(2):134-41. doi:10.1111/j.1442-2042.2011.02906.x
  108. Latte KP, Appel KE, Lampen A. Health benefits and possible risks of broccoli - an overview. Food Chem Toxicol. Dec 2011;49(12):3287-3309. doi:10.1016/j.fct.2011.08.019
  109. Zhang Y. Allyl isothiocyanate as a cancer chemopreventive phytochemical. Mol Nutr Food Res. Jan 2010;54(1):127-35. doi:10.1002/mnfr.200900323
  110. Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. May 2007;64(9):1105-27. doi:10.1007/s00018-007-6484-5
  111. Mitrou PN, Kipnis V, Thiebaut AC, et al. Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med. Dec 10 2007;167(22):2461-2468. doi:10.1001/archinte.167.22.2461
  112. Buckland G, Travier N, Cottet V, et al. Adherence to the mediterranean diet and risk of breast cancer in the European prospective investigation into cancer and nutrition cohort study. Int J Cancer. Jun 15 2013;132(12):2918-27. doi:10.1002/ijc.27958
  113. Couto E, Sandin S, Lof M, Ursin G, Adami HO, Weiderpass E. Mediterranean dietary pattern and risk of breast cancer. PLoS One. 2013;8(2):e55374. doi:10.1371/journal.pone.0055374
  114. Bamia C, Lagiou P, Buckland G, et al. Mediterranean diet and colorectal cancer risk: results from a European cohort. Eur J Epidemiol. Apr 2013;28(4):317-328. doi:10.1007/s10654-013-9795-x
  115. Bosetti C, Turati F, Dal Pont A, et al. The role of Mediterranean diet on the risk of pancreatic cancer. Br J Cancer. Sep 3 2013;109(5):1360-6. doi:10.1038/bjc.2013.345
  116. Kenfield SA, DuPre N, Richman EL, Stampfer MJ, Chan JM, Giovannucci EL. Mediterranean diet and prostate cancer risk and mortality in the health professionals follow-up study. Eur Urol. May 2014;65(5):887-94. doi:10.1016/j.eururo.2013.08.009
  117. The Mediterranean Diet Pyramid. Accessed July 21, 2014, https://dietamediterranea.com/piramidedm/piramide_INGLES.pdf
  118. Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. Aug 2013;17(4):273-84. doi:10.1016/j.smrv.2012.08.003
  119. Bovbjerg DH. Circadian disruption and cancer: sleep and immune regulation. Brain Behav Immun. Feb 2003;17 Suppl 1:S48-50.
  120. Malina C, Frigo S, Mathelin C. [Sleep and breast cancer: is there a link?]. Gynecologie, obstetrique & fertilite. Feb 2013;41(2):105-9. Sommeil et cancer du sein : existe-t-il un lien ? doi:10.1016/j.gyobfe.2012.12.008
  121. Qin Y, Zhou Y, Zhang X, Wei X, He J. Sleep duration and breast cancer risk: a meta-analysis of observational studies. Int J Cancer. Mar 1 2014;134(5):1166-73. doi:10.1002/ijc.28452
  122. Gottlieb BH, Wachala ED. Cancer support groups: a critical review of empirical studies. Psychooncology. May 2007;16(5):379-400. doi:10.1002/pon.1078
  123. Mustafa M, Carson-Stevens A, Gillespie D, Edwards AG. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev. 2013;6:Cd004253. doi:10.1002/14651858.CD004253.pub4
  124. Hoey LM, Ieropoli SC, White VM, Jefford M. Systematic review of peer-support programs for people with cancer. Patient Educ Couns. Mar 2008;70(3):315-37. doi:10.1016/j.pec.2007.11.016
  125. Piderman KM, Kung S, Jenkins SM, et al. Respecting the spiritual side of advanced cancer care: a systematic review. Curr Oncol Rep. Feb 2015;17(2):6. doi:10.1007/s11912-014-0429-6
  126. Elkins G, Fisher W, Johnson A. Mind-body therapies in integrative oncology. Curr Treat Options Oncol. Dec 2010;11(3-4):128-40. doi:10.1007/s11864-010-0129-x
  127. Carlson LE, Bultz BD. Mind-body interventions in oncology. Curr Treat Options Oncol. Jun 2008;9(2-3):127-34. doi:10.1007/s11864-008-0064-2
  128. Cramer H, Lauche R, Paul A, Dobos G. Mindfulness-based stress reduction for breast cancer-a systematic review and meta-analysis. Curr Oncol. Oct 2012;19(5):e343-52. doi:10.3747/co.19.1016
  129. Matchim Y, Armer JM, Stewart BR. Mindfulness-based stress reduction among breast cancer survivors: a literature review and discussion. Oncology Nursing Forum. Mar 2011;38(2):E61-71. doi:10.1188/11.onf.e61-e71
  130. Rush SE, Sharma M. Mindfulness-based stress reduction as a stress management intervention for cancer care: a systematic review. J Evid Based Complementary Altern Med. Apr 2017;22(2):348-360. doi:10.1177/2156587216661467
  131. Kapogiannis A, Tsoli S, Chrousos G. Investigating the effects of the progressive muscle relaxation-guided imagery combination on patients with cancer receiving chemotherapy treatment: a systematic review of randomized controlled trials. Explore (NY). Mar-Apr 2018;14(2):137-143. doi:10.1016/j.explore.2017.10.008
  132. Alschuler LN, Gazella KA. The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. 3rd ed. Celestial Arts; 2010.
  133. National Cancer Institute. Radiation Therapy for Cancer Fact Sheet. Accessed July 29, 2014, http://www.cancer.gov/cancertopics/factsheet/Therapy/radiation
  134. National Cancer Institute. Chemotherapy and You: Support for People with Cancer. Accessed July 29, 2014, https://www.cancer.gov/publications/patient-education/chemo-and-you
  135. Myers CD, Walton T, Bratsman L, Wilson J, Small B. Massage modalities and symptoms reported by cancer patients: narrative review. J Soc Integr Oncol. Winter 2008;6(1):19-28.
  136. Fellowes D, Barnes K, Wilkinson S. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database Syst Rev. 2004;(2):Cd002287. doi:10.1002/14651858.CD002287.pub2
  137. Deng G, Vickers A, Simon YK, Cassileth B. Acupuncture: integration into cancer care. Journal of the Society for Integrative Oncology. 2005;4(2):86-92.
  138. Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. Mar 1 2013;31(7):952-60. doi:10.1200/jco.2012.43.5818
  139. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. Jun 2010;121(2):469-77. doi:10.1007/s10549-009-0593-9
  140. Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T. Vitamin D exposure and risk of breast cancer: a meta-analysis. Sci Rep. Jun 13 2018;8(1):9039. doi:10.1038/s41598-018-27297-1
  141. Hossain S, Beydoun MA, Beydoun HA, Chen X, Zonderman AB, Wood RJ. Vitamin D and breast cancer: A systematic review and meta-analysis of observational studies. Clinical nutrition ESPEN. Apr 2019;30:170-184. doi:10.1016/j.clnesp.2018.12.085
  142. Tommie JL, Pinney SM, Nommsen-Rivers LA. Serum vitamin D status and breast cancer risk by receptor status: A systematic review. Nutr Cancer. Jul 2018;70(5):804-820. doi:10.1080/01635581.2018.1470653
  143. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. Mar 2007;32(3):210-6. doi:10.1016/j.amepre.2006.11.004
  144. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. Oct 1 2011;29(28):3775-82. doi:10.1200/jco.2011.35.7566
  145. Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res. 2011;4(5):735-743.
  146. Hu MJ, Zhang Q, Liang L, et al. Association between vitamin D deficiency and risk of thyroid cancer: a case-control study and a meta-analysis. J Endocrinol Invest. Oct 2018;41(10):1199-1210. doi:10.1007/s40618-018-0853-9
  147. Zhao J, Wang H, Zhang Z, et al. Vitamin D deficiency as a risk factor for thyroid cancer: A meta-analysis of case-control studies. Nutrition. Jan 2019;57:5-11. doi:10.1016/j.nut.2018.04.015
  148. Liao Y, Huang JL, Qiu MX, Ma ZW. Impact of serum vitamin D level on risk of bladder cancer: a systemic review and meta-analysis. Tumour Biol. Mar 2015;36(3):1567-72. doi:10.1007/s13277-014-2728-9
  149. Chen F, Li Q, Yu Y, Yang W, Shi F, Qu Y. Association of vitamin C, vitamin D, vitamin E and risk of bladder cancer: a dose-response meta-analysis. Sci Rep. Apr 23 2015;5:9599. doi:10.1038/srep09599
  150. Zhao Y, Chen C, Pan W, et al. Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis. Nutrition. May 2016;32(5):515-23. doi:10.1016/j.nut.2015.10.023
  151. Wei H, Jing H, Wei Q, Wei G, Heng Z. Associations of the risk of lung cancer with serum 25-hydroxyvitamin D level and dietary vitamin D intake: A dose-response PRISMA meta-analysis. Medicine (Baltimore). Sep 2018;97(37):e12282. doi:10.1097/md.0000000000012282
  152. Zhang L, Wang S, Che X, Li X. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem. 2015;36(1):299-305. doi:10.1159/000374072
  153. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control. Mar 2011;22(3):319-40. doi:10.1007/s10552-010-9706-3
  154. Yin L, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. Dec 2009;33(6):435-45. doi:10.1016/j.canep.2009.10.014
  155. Huncharek M, Muscat J, Kupelnick B. Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer. 2008;60(4):421-41. doi:10.1080/01635580801911779
  156. Petrou S, Mamais I, Lavranos G, I PT, Chrysostomou S. Effect of vitamin D supplementation in prostate cancer: A systematic review of randomized control trials. Int J Vitam Nutr Res. Feb 2018;88(1-2):100-112. doi:10.1024/0300-9831/a000494
  157. Zgaga L, O'Sullivan F, Cantwell MM, Murray LJ, Thota PN, Coleman HG. Markers of Vitamin D Exposure and Esophageal Cancer Risk: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. Jun 2016;25(6):877-86. doi:10.1158/1055-9965.Epi-15-1162
  158. Khayatzadeh S, Feizi A, Saneei P, Esmaillzadeh A. Vitamin D intake, serum Vitamin D levels, and risk of gastric cancer: A systematic review and meta-analysis. J Res Med Sci. Aug 2015;20(8):790-6. doi:10.4103/1735-1995.168404
  159. Peiris AN, Bailey BA, Manning T. Relationship of vitamin D monitoring and status to bladder cancer survival in veterans. South Med J. Feb 2013;106(2):126-30. doi:10.1097/SMJ.0b013e3182824d00
  160. Goulão B, Stewart F, Ford JA, MacLennan G, Avenell A. Cancer and vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. Apr 1 2018;107(4):652-663. doi:10.1093/ajcn/nqx047
  161. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2008;3
  162. Chang YJ, Myung SK, Chung ST, et al. Effects of vitamin treatment or supplements with purported antioxidant properties on skin cancer prevention: a meta-analysis of randomized controlled trials. Dermatology. 2011;223(1):36-44. doi:10.1159/000329439
  163. Jiang L, Yang K-h, Tian J-h, et al. Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials. Nutr Cancer. 2010;62(6):719-727.
  164. Papaioannou D, Cooper K, Carroll C, et al. Antioxidants in the chemoprevention of colorectal cancer and colorectal adenomas in the general population: a systematic review and meta‐analysis. Colorectal Dis. 2011;13(10):1085-1099.
  165. Coulter ID, Hardy ML, Morton SC, et al. Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med. Jul 2006;21(7):735-44. doi:10.1111/j.1525-1497.2006.00483.x
  166. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M. Selenium for preventing cancer. Cochrane Database Syst Rev. 2011;(5):Cd005195. doi:10.1002/14651858.CD005195.pub2
  167. Myung SK, Kim Y, Ju W, Choi HJ, Bae WK. Effects of antioxidant supplements on cancer prevention: meta-analysis of randomized controlled trials. Ann Oncol. Jan 2010;21(1):166-179. doi:10.1093/annonc/mdp286
  168. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. May 2 1996;334(18):1150-5. doi:10.1056/nejm199605023341802
  169. Cretu E, Trifan A, Vasincu A, Miron A. Plant-derived anticancer agents - curcumin in cancer prevention and treatment. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. Oct-Dec 2012;116(4):1223-9.
  170. Frenkel M, Abrams DI, Ladas EJ, et al. Integrating dietary supplements into cancer care. Integr Cancer Ther. Sep 2013;12(5):369-84. doi:10.1177/1534735412473642
  171. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919-30. doi:10.1080/01635581.2010.509835
  172. Ogunleye AA, Xue F, Michels KB. Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res Treat. Jan 2010;119(2):477-84. doi:10.1007/s10549-009-0415-0
  173. Gianfredi V, Nucci D, Abalsamo A, et al. Green tea consumption and risk of breast cancer and recurrence-A systematic review and meta-analysis of observational studies. Nutrients. Dec 3 2018;10(12)doi:10.3390/nu10121886
  174. Najaf Najafi M, Salehi M, Ghazanfarpour M, Hoseini ZS, Khadem-Rezaiyan M. The association between green tea consumption and breast cancer risk: A systematic review and meta-analysis. Phytother Res. Oct 2018;32(10):1855-1864. doi:10.1002/ptr.6124
  175. Yu S, Zhu L, Wang K, Yan Y, He J, Ren Y. Green tea consumption and risk of breast cancer: A systematic review and updated meta-analysis of case-control studies. Medicine (Baltimore). Jul 2019;98(27):e16147. doi:10.1097/md.0000000000016147
  176. Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer. 2012;64(1):4-22. doi:10.1080/01635581.2012.630158
  177. Zheng J, Yang B, Huang T, Yu Y, Yang J, Li D. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer. 2011;63(5):663-72. doi:10.1080/01635581.2011.570895
  178. Jacob SA, Khan TM, Lee LH. The effect of green tea consumption on prostate cancer risk and progression: a systematic review. Nutr Cancer. Apr 2017;69(3):353-364. doi:10.1080/01635581.2017.1285037
  179. Guo Y, Zhi F, Chen P, et al. Green tea and the risk of prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore). Mar 2017;96(13):e6426. doi:10.1097/md.0000000000006426
  180. Mirtavoos-Mahyari H, Salehipour P, Parohan M, Sadeghi A. Effects of coffee, black tea and green tea consumption on the risk of non-hodgkin's lymphoma: A systematic review and dose-response meta-analysis of observational studies. Nutr Cancer. 2019;71(6):887-897. doi:10.1080/01635581.2019.1595055
  181. Lee AH, Su D, Pasalich M, Binns CW. Tea consumption reduces ovarian cancer risk. Cancer Epidemiol. Feb 2013;37(1):54-9. doi:10.1016/j.canep.2012.10.003
  182. Tang N-P, Li H, Qiu Y-L, Zhou G-M, Ma J. Tea consumption and risk of endometrial cancer: a metaanalysis. Am J Obstet Gynecol. 2009;201(6):605. e1-605. e8.
  183. Trudel D, Labbe DP, Bairati I, Fradet V, Bazinet L, Tetu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. Gynecol Oncol. Sep 2012;126(3):491-8. doi:10.1016/j.ygyno.2012.04.048
  184. Je Y, Park T. Tea consumption and endometrial cancer risk: meta-analysis of prospective cohort studies. Nutr Cancer. 2015;67(5):825-30. doi:10.1080/01635581.2015.1040521
  185. Zhang D, Kaushiva A, Xi Y, Wang T, Li N. Non-herbal tea consumption and ovarian cancer risk: a systematic review and meta-analysis of observational epidemiologic studies with indirect comparison and dose-response analysis. Carcinogenesis. May 28 2018;39(6):808-818. doi:10.1093/carcin/bgy048
  186. Zhou Q, Li H, Zhou JG, Ma Y, Wu T, Ma H. Green tea, black tea consumption and risk of endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. Jan 2016;293(1):143-155. doi:10.1007/s00404-015-3811-1
  187. Zheng JS, Yang J, Fu YQ, Huang T, Huang YJ, Li D. Effects of green tea, black tea, and coffee consumption on the risk of esophageal cancer: a systematic review and meta-analysis of observational studies. Nutr Cancer. 2013;65(1):1-16. doi:10.1080/01635581.2013.741762
  188. Zheng P, Zheng HM, Deng XM, Zhang YD. Green tea consumption and risk of esophageal cancer: a meta-analysis of epidemiologic studies. BMC Gastroenterol. 2012;12:165. doi:10.1186/1471-230x-12-165
  189. Myung SK, Bae WK, Oh SM, et al. Green tea consumption and risk of stomach cancer: a meta-analysis of epidemiologic studies. Int J Cancer. Feb 1 2009;124(3):670-7. doi:10.1002/ijc.23880
  190. Huang Y, Chen H, Zhou L, et al. Association between green tea intake and risk of gastric cancer: a systematic review and dose-response meta-analysis of observational studies. Public Health Nutr. Dec 2017;20(17):3183-3192. doi:10.1017/s1368980017002208
  191. Fon Sing M, Yang WS, Gao S, Gao J, Xiang YB. Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. Eur J Cancer Prev. May 2011;20(3):157-65. doi:10.1097/CEJ.0b013e3283447497
  192. Huang YQ, Lu X, Min H, et al. Green tea and liver cancer risk: A meta-analysis of prospective cohort studies in Asian populations. Nutrition. Jan 2016;32(1):3-8. doi:10.1016/j.nut.2015.05.021
  193. Ni CX, Gong H, Liu Y, Qi Y, Jiang CL, Zhang JP. Green tea consumption and the risk of liver cancer: a meta-analysis. Nutr Cancer. Feb-Mar 2017;69(2):211-220. doi:10.1080/01635581.2017.1263754
  194. Tanaka K, Tamakoshi A, Sugawara Y, et al. Coffee, green tea and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. Oct 1 2019;49(10):972-984. doi:10.1093/jjco/hyz097
  195. Wang ZH, Gao QY, Fang JY. Green tea and incidence of colorectal cancer: evidence from prospective cohort studies. Nutr Cancer. 2012;64(8):1143-52. doi:10.1080/01635581.2012.718031
  196. Chen Y, Wu Y, Du M, et al. An inverse association between tea consumption and colorectal cancer risk. Oncotarget. Jun 6 2017;8(23):37367-37376. doi:10.18632/oncotarget.16959
  197. Seely D, Wu P, Fritz H, et al. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. Dec 2012;11(4):293-303. doi:10.1177/1534735411425484
  198. Wang CW, Ng SM, Ho RT, Ziea ET, Wong VC, Chan CL. The effect of qigong exercise on immunity and infections: a systematic review of controlled trials. Am J Chin Med. 2012;40(6):1143-56. doi:10.1142/s0192415x1250084x

Keywords:
Cancer care, exercise, environmental exposures, nutrition, support groups, conventional approaches, surgery, chemotherapy, radiation, complementary approaches 
Doc ID:
150554
Owned by:
Sara A. in Osher Center for Integrative Health
Created:
2025-05-12
Updated:
2026-04-15
Sites:
Osher Center for Integrative Health
Clean URL:
https://kb.wisc.edu/osher/cancer-care-overview